CVRX Stock Forecast: CVRx, Inc. Price Predictions for 2026-2027
The 7 Wall Street analysts covering CVRx, Inc. hold a median 12-month price target of $1.5 — +189.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 20 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores CVRx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (74): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CVRX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CVRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +189.6% from it.
Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | Cantor Fitzgerald | Maintains | Overweight | $5.00 → $2.00 |
| 7 Nov 2026 | Lake Street | Maintains | Hold | — |
| 6 Nov 2026 | Canaccord Genuity | Downgrade | Hold | $5.00 → $2.00 |
| 6 Nov 2026 | Lake Street | Maintains | Hold | $3.50 → $1.50 |
| 6 Nov 2026 | William Blair | Downgrade | Market Perform | — |
| 17 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $13 → $5.00 |
| 8 Aug 2026 | Lake Street | Downgrade | Hold | — |
| 7 Aug 2026 | Lake Street | Downgrade | Hold | $14 → $3.50 |
| 14 Apr 2026 | Canaccord Genuity | Maintains | Buy | $10 |
| 13 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 Nov 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 5 Aug 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 May 2025 | JP Morgan | Downgrade | Underweight | — |
| 9 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 8 Apr 2025 | Canaccord Genuity | Maintains | Buy | — |
| 8 Apr 2025 | Lake Street | Maintains | Buy | — |
| 5 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 5 Feb 2025 | Piper Sandler | Maintains | Overweight | — |
| 17 Jan 2025 | Craig-Hallum | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CVRX.
This page is one stock. Monday covers all of them.
CVRX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CVRX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, CVRx, Inc. returned −94.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CVRX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.2×
- Price / book
- 1.0×
- EV / EBITDA
- —
Cheaper than 89% of US stocks
Cheaper than 69% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 87.4%
- Operating margin
- −81.9%
- Net margin
- −88.3%
Higher than 95% of US stocks
Higher than 15% of US stocks
Higher than 7% of US stocks
- Return on equity
- −172.2%
- Return on assets
- −31.0%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CVRx, Inc. has a market value of $14.3M and an enterprise value of $14.9M.
Revenue in the twelve months to 30 June 2026: $61.2M. The latest quarter grew 15.6% year on year.
Net income over the same four quarters: −$52.0M, a −84.9% net margin.
Diluted earnings per share, trailing twelve months: −$1.98.
Free cash flow in the twelve months to 30 June 2026: −$41.1M.
CVRx, Inc. employs 223 people — $274K of revenue per employee.
Data provided by Twelve Data
CVRX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CVRX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own CVRx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CVRX
What is the CVRX stock price forecast for 2026-2027?
The 7 Wall Street analysts covering CVRx, Inc. have a median 12-month price target of $1.5, with estimates ranging from $1.25 to $2. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CVRX stock a buy right now?
Of the 7 analysts covering CVRx, Inc., 1 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks CVRx, Inc. 20 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CVRX?
As at 21 Nov 2026, CVRx, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (74 of 100).
Will CVRX stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +189.6% from the last close, and Ticker Nerd's factor model ranks CVRx, Inc. 20 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CVRX stock forecast for 2030?
No analyst covering CVRx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.25 to $2 over the next 12 months.
How has CVRX stock performed over the past year?
CVRx, Inc. returned -94.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does CVRx, Inc. do?
CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease. Its flagship product, Barostim, is an implantable therapy system that delivers electrical pulses to carotid baroreceptors to help regulate autonomic nervous system activity and support cardiovascular function.
About CVRx, Inc.
CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease. Its flagship product, Barostim, is an implantable therapy system that delivers electrical pulses to carotid baroreceptors to help regulate autonomic nervous system activity and support cardiovascular function. The company’s current offerings center on Baroreflex Activation Therapy, a minimally invasive treatment approach used for patients with heart failure and other cardiovascular conditions. CVRx develops, manufactures, and commercializes its products in the United States, Germany, and selected international markets through direct sales and distribution channels. Headquartered in Minneapolis, Minnesota, CVRx plays a specialized role in the medical technology market by providing device-based therapies that address complex cardiac care needs.
CEO Mr. Kevin Hykes · 223 employees · United States · https://www.barostim.com